CardieX Limited ( (AU:CDX) ) just unveiled an announcement.
Cardiex Limited reported a significant decrease in revenues by 83% for the half-year ending December 31, 2024, compared to the same period in 2023, resulting in a net loss of $6,973,605. This financial downturn marks a stark contrast to the previous year’s profit, reflecting challenges that may impact the company’s market positioning and stakeholder confidence.
More about CardieX Limited
Cardiex Limited is a company focused on advancing medical technology for vascular health, offering products such as medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. The company is known for its SphygmoCor® vascular biomarker technology and is listed on the Australian Stock Exchange (ASX:CDX).
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $28.99M
See more data about CDX stock on TipRanks’ Stock Analysis page.